NARA Discovery
Article Details
← Back to Search Results
Journal Article

Using Pre-Clinical Studies to Explore the Potential Clinical Uses of Exosomes Secreted from Induced Pluripotent Stem Cell-Derived Mesenchymal Stem cells

Andrew Kailin Zhou; Eric Jou; Victor Lu; James Zhang; Shirom Chabra; Joshua Abishek; Ethan Wong; Xianwei Zeng; Baoqiang Guo
Tissue Engineering and Regenerative Medicine · Vol. 20, Issue 6 · pp. 793-809 · 2023

Abstract

Recent studies of exosomes derived from mesenchymal stem cells (MSCs) have indicated high potential clinical applications in many diseases. However, the limited source of MSCs impedes their clinical research and application. Most recently, induced pluripotent stem cells (iPSCs) have become a promising source of MSCs. Exosome therapy based on iPSC-derived MSCs (iMSCs) is a novel technique with much of its therapeutic potential untapped. Compared to MSCs, iMSCs have proved superior in cell proliferation, immunomodulation, generation of exosomes capable of controlling the microenvironment, and bioactive paracrine factor secretion, while also theoretically eliminating the dependence on immunosuppression drugs. The therapeutic effects of iMSC-derived exosomes are explored in many diseases and are best studied in wound healing, cardiovascular disease, and musculoskeletal pathology. It is pertinent clinicians have a strong understanding of stem cell therapy and the latest advances that will eventually translate into clinical practice. In this review, we discuss the various applications of exosomes derived from iMSCs in clinical medicine.

Bibliographic Information

JournalTissue Engineering and Regenerative Medicine
PublisherSpringer
Publication Date2023-10-01
Publication Year2023
Volume20
Issue6
Pages793-809
Document TypeJournal Article
Print ISSN1738-2696
eISSN2212-5469
DOI10.1007/s13770-023-00557-6

Access Information

NARA Access Coverage2012-01-01~Current
Journal Homepagehttps://www.springer.com/journal/13770
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.